MUC16 and ovarian carcinoma: Based on the summation of these findings and evidence of efficacy against human ovarian tumors in SCID-beige models37, we are currently undertaking a phase I clinical trial to evaluate safety of armored IL-12 secreting CAR T cells in Muc-16+ ovarian carcinoma (NCT02498912).